HK1143066A1 - Ranolazine for elevated brain-type natriuretic peptide - Google Patents

Ranolazine for elevated brain-type natriuretic peptide

Info

Publication number
HK1143066A1
HK1143066A1 HK10109528.0A HK10109528A HK1143066A1 HK 1143066 A1 HK1143066 A1 HK 1143066A1 HK 10109528 A HK10109528 A HK 10109528A HK 1143066 A1 HK1143066 A1 HK 1143066A1
Authority
HK
Hong Kong
Prior art keywords
ranolazine
natriuretic peptide
type natriuretic
elevated brain
coronary
Prior art date
Application number
HK10109528.0A
Other languages
English (en)
Inventor
Brent Blackburn
Marcus Jerling
Andrew Wolff
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1143066A1 publication Critical patent/HK1143066A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10109528.0A 2007-05-31 2010-10-06 Ranolazine for elevated brain-type natriuretic peptide HK1143066A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94121007P 2007-05-31 2007-05-31
PCT/US2008/058063 WO2008150565A2 (en) 2007-05-31 2008-03-24 Ranolazine for elevated brain-type natriuretic peptide

Publications (1)

Publication Number Publication Date
HK1143066A1 true HK1143066A1 (en) 2010-12-24

Family

ID=39929825

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10109528.0A HK1143066A1 (en) 2007-05-31 2010-10-06 Ranolazine for elevated brain-type natriuretic peptide

Country Status (12)

Country Link
US (1) US20080299195A1 (xx)
EP (1) EP2170333B1 (xx)
KR (1) KR20100033490A (xx)
CN (1) CN101896181A (xx)
CA (1) CA2689633A1 (xx)
EA (1) EA200971073A1 (xx)
EC (1) ECSP099828A (xx)
ES (1) ES2402675T3 (xx)
HK (1) HK1143066A1 (xx)
IL (1) IL202493A0 (xx)
WO (1) WO2008150565A2 (xx)
ZA (1) ZA200908657B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
KR101030943B1 (ko) 2002-05-21 2011-04-28 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ATE142497T1 (de) * 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
BR0108452A (pt) * 2000-02-18 2003-04-01 Cv Therapeutics Inc Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
US20030220312A1 (en) * 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
ATE357257T1 (de) * 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
EP1541175A3 (en) * 2001-01-26 2006-04-12 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
DE10126328A1 (de) * 2001-05-30 2002-12-12 Infineon Technologies Ag Integrierte, abstimmbare Kapazität
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
AU2003210975A1 (en) * 2002-02-08 2003-09-02 Mitokor Compounds for inhibiting insulin secretion and methods related thereto
HUP0402591A2 (hu) * 2002-02-15 2005-09-28 Cv Therapeutics, Inc. Polimer bevonat orvosi eszközök számára
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
KR101030943B1 (ko) * 2002-05-21 2011-04-28 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2517981A1 (en) * 2003-03-05 2004-09-16 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
US8071645B2 (en) * 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2005002597A1 (en) * 2003-07-02 2005-01-13 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
JP2008500347A (ja) * 2004-05-24 2008-01-10 ニュー・ヨーク・ユニヴァーシティー 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
CA2586840A1 (en) * 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
AU2006223212A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
JP2010514696A (ja) * 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
WO2010068461A1 (en) * 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン

Also Published As

Publication number Publication date
EA200971073A1 (ru) 2010-08-30
WO2008150565A2 (en) 2008-12-11
ECSP099828A (es) 2010-01-29
ZA200908657B (en) 2010-08-25
CN101896181A (zh) 2010-11-24
EP2170333A2 (en) 2010-04-07
AU2008260480A1 (en) 2008-12-11
EP2170333B1 (en) 2013-02-20
ES2402675T8 (es) 2013-06-25
WO2008150565A3 (en) 2009-04-02
CA2689633A1 (en) 2008-12-11
IL202493A0 (en) 2011-07-31
ES2402675T3 (es) 2013-05-07
KR20100033490A (ko) 2010-03-30
US20080299195A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
HK1143066A1 (en) Ranolazine for elevated brain-type natriuretic peptide
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
MX2019006731A (es) Uso de insulina de accion ultrarrapida.
CL2011000553A1 (es) Metodo de tratamiento de esclerosis multiple progresiva, que comprende administrar un anticuerpo anti-cd20 a un paciente con edad inferior a 55 años y/o con lesiones que tiñen con gadolinio y/o con al menos un aumento de 1 punto edss y/o con un puntaje msss superior a 5 puntos; metodo de diagnostico; y articulo manufacturado.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
EG25239A (en) Container with a hollow needle.
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
CO6531499A2 (es) Uso de ranolazina para el tratameinto de enfermedades cardiovasculares
AR061352A1 (es) El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
MD3987C2 (ro) Utilizare a Diosminei pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă
AR077460A1 (es) Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple
RU2007129578A (ru) Способ комплексного лечения остроконечных кондилом урогенитального тракта
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
PL372345A1 (en) Treatment of type i diabetes mellitus using growth hormone antagonist
MD3986C2 (ro) Utilizare a Diosminei pentru tratamentul gastropatiilor portale în ciroza hepatică
UA85141C2 (ru) Способ лечения метаболического синдрома x
UA47974U (ru) Способ контролируемого лечения болезни альцгеймера 1 типа пиоглитазоном у лиц с инсулинорезистентностью
UA27829U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome
UA27830U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome
UA42947U (ru) Способ экспериментальной коррекции травматических повреждений роговицы
RU2008148383A (ru) Применение рилменидина для лечения синдрома обструктивного апноэ во сне у больных артериальной гипертензией

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200323